All In Biotech

Investigational drug · Phase 3

Pemvidutide

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD).

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

2 still active

All registered trials

8

Any phase or sponsor naming "Pemvidutide"

First trial start

2023

Jul 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Pemvidutide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alcohol-associated Liver Disease
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Alcohol Use Disorder (AUD)
  • Non-Alcoholic Steatohepatitis (NASH)

Approved drugs for the same conditions: Alcohol dependence · MASH (fatty liver disease) · Psychiatry · Infectious disease and vaccines · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Pemvidutide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 16 on PubMed

Also in development for Alcohol-associated Liver Disease

  • ALN-CIDEBPhase 34 trials

    Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.